

CUMULATIVE INDEX 2001

Volume 27

February	OSTEOPOROSIS , pages 1-268
May	RHEUMATOID ARTHRITIS , pages 269-497
August	ANTIPHOSPHOLIPID (HUGHES) SYNDROME , pages 499-675
November	VASCULITIS , pages 677-926

Note: Page numbers of article titles are in **boldface** type

- Absorptiometry, in bone density measurement
 dual X-ray, 83, 98-99
 single photon, 82
- Acid phosphatase, tartrate-resistant, as bone turnover marker, 53-55
- aCL. *See* Anticardiolipin antibody.
- Activator protein 1, in rheumatoid arthritis pathogenesis, 360-361
- Adhesion molecules
 in T-lymphocyte migration, 318
 inhibitors of, for rheumatoid arthritis, 381, 463-464
- Aggrecan
 antibodies to, in rheumatoid arthritis pathogenesis, 342-343
 degradation of, in rheumatoid arthritis, 364
- Alcohol use, smoking and, 31
- Alendronate, for osteoporosis, 168-169, 178, 202-205
 estrogens with, 152
 glucocorticoid-induced, 246
 in men, 37-38
 pharmacodynamics of, 199-200
 side effects of, 201
- Alkaline phosphatase, as marker for bone formation, 50-52
- Allen's test, in Buerger's disease, 721-722
- Alveolar hemorrhage, in microscopic polyangiitis, 706
- Amaurosis fugax, in giant cell arteritis, 781
- Amenorrhea, bone status in, 137
- Amyloidosis, cerebral, versus vasculitis, 718-719
- Amyotrophy, diabetic, 756-757
- Anabolic agents, for osteoporosis, **215-233**
 glucocorticoid-induced, 246-247
 growth hormone, 217-221
 insulin-like growth factor 1, 221-222
 mechanisms of action of, 216-217
 parathyroid hormone, 222-231, 247-248
 safety issues with, 228-229
- ANCA's. *See* Anti-neutrophil cytoplasmic antibodies.
- Androgens. *See also* Testosterone.
 for osteoporosis
 estrogens with, 150-151
 fracture risk and, 28-30
- Anemia, hemolytic, in antiphospholipid syndrome, 517-518
- Aneurysms, in giant cell arteritis, 681, 683
- Angiitis
 central nervous system
 histologically defined, 715-717
 isolated, epidemiology of, 734
 leukocytoclastic, cutaneous, 741
 microscopic. *See* Microscopic polyangiitis.
- Angiogenesis inhibitors, for rheumatoid arthritis, 383, 463-464
- Angiography
 cerebral, in vasculitis, 717-718
 in Takayasu's arteritis, 711, 713
 visceral abdominal, in polyarteritis nodosa, 680-681
- Angiopathy, of central nervous system, angiographically defined, 715, 719
- Annexins, in coagulation, antiphospholipid antibodies and, 582, 595
- Anti-glomerular basement membrane disease, in microscopic polyangiitis, 706
- Anti-neutrophil cytoplasmic antibodies atypical, in vasculitis, 805

Anti-neutrophil cytoplasmic antibodies

(Continued)

- bactericidal/permeability-increasing protein-directed, 803, 805, 808
- disorders related to, 801
- in Churg-Strauss syndrome, 804, 836
- in glomerulonephritis, 708
- in microscopic polyangiitis, 707, 836, 842
- in necrotizing crescentic progressive glomerulonephritis, 836-840, 842, 892
- in rheumatoid arthritis, 801
- in systemic lupus erythematosus, 801
- in vasculitis, 734-736, **887-903**
 - antibody types and, 835
 - antigens involved in, 840-843
 - atypical, 805
 - cell-mediated immunity in, 894-897
 - drug-induced, 853-854
 - endothelial cells and, 820-822, 893-894, 897
 - etiology of, 897-898
 - immune complexes in, 833-834, 838-843
 - monocyte interactions in, 889, 894, 896-897
 - neutrophil interactions in, 888-893
 - pathology of, 887-888
 - pathophysiology of, 833-837
 - pauci-immune lesions in, 837-838
 - serological tests for, **799-813**
 - types of, 836
- in Wegener's granulomatosis, 702, 836, 839-840, 842-843
 - monocyte interactions in, 822-823
 - serologic testing and, 800, 804, 808
- myeloperoxidase-directed
 - endothelial effects of, 820-822, 891-892
 - in animal models, 823-825
 - in vasculitis, 801, 804-809
 - unanswered questions concerning, 825-826
 - neutrophil effects of, 817-819, 888-889
 - pathophysiologic relevance of, 836-837
 - T cell interactions with, 895
 - versus proteinase 3-directed, 888-889
- pathogenicity of, **815-832, 833-848, 887-903**
 - animal models of, 823-825
 - antibody types and, 835
 - cell-mediated immunity in, 894-897
 - characteristics of, 833-835
 - endothelial cells and, 820-822, 893-894, 897
 - immune complexes and, 833-834, 838-843
 - in vasculitis, 836-843. *See* Anti-neutrophil cytoplasmic antibodies, in vasculitis.

- in vitro studies of, 816-823
 - monocytes and macrophages and, 822-823, 889, 894, 896-897
 - neutrophils and, 817-820, 888-893
 - pauci-immune lesions in, 837-838
 - unanswered questions in, 825-827
 - perinuclear, in vasculitis, 803-807
 - proteinase 3-directed
 - endothelial effects of, 820-822, 891
 - in vasculitis, 801, 803, 806-809, 825-826
 - neutrophil effects of, 817-819, 888-889, 892
 - pathophysiologic relevance of, 836-837
 - T cell interactions with, 895
 - versus myeloperoxidase-directed, 888-889
 - serological tests for, **799-813**
 - antigen capture principle in, 809
 - availability of, 807
 - clinical considerations in, 800-801, 807
 - enzyme immunoassay, 805-807
 - immunofluorescent, 802-805
 - immunoprecipitation, 809
 - in vasculitis, 808-809
 - results reporting, 807
 - stains for, 835
- Antibody(ies)
- CD4 molecule, in rheumatoid arthritis, 447-449
 - CD5 molecule, in rheumatoid arthritis, 449
 - endothelial cell, in vasculitis, 834-835, 842, 893-894
 - etanercept, 434-435
 - glomerular basement membrane
 - in microscopic polyangiitis, 707
 - in vasculitis, 834-835
 - hepatitis C virus, 709
 - in rheumatoid arthritis pathogenesis, 339-343
 - infliximab, 430-431
 - interleukin-2 receptor, in rheumatoid arthritis, 449-450
 - monoclonal. *See* Monoclonal antibodies.
 - neutrophil cytoplasmic. *See* Anti-neutrophil cytoplasmic antibodies.
 - normal development and selection of, 337-339
 - structure of, 337
- Anticardiolipin antibody
- in antiphospholipid syndrome, 501
 - heart disease and, 512-514, 665
 - prognosis and, 661-662
 - stroke and, 508
 - in syphilis, 551-552
 - in transplantation
 - bone marrow, 624-625
 - heart, 621-622

- kidney, 614-618
tests for, 532-536
- Anticoagulants, for antiphospholipid syndrome
acute, 633-634
catastrophic, 634-635
chronic, 635-640
prognosis in, 666
- Antigen(s), in vasculitis
anti-neutrophil cytoplasmic antibodies directed to, 840-843
bacterial, in 842-843
endothelial cell, 842
- Antigen-antibody (immune) complexes, in vasculitis, anti-neutrophil cytoplasmic antibodies and, 833-834, 838-843
- Antiphospholipid antibodies. *See also* Antiphospholipid (Hughes) syndrome; *specific antibodies*.
atherosclerosis and, 603-610
coagulation cascade and, 573-586
endothelial interactions with, 587-602
in syphilis, 551-552
origin of, 551-563
animal studies of, 553-558
 β_2 -glycoprotein cofactor and, 554-556, 558-559
historical background of, 551-553
molecular mimicry and, 556-559
peptide immunization, 555-559
tests for, 501, 525-549, 583
current status of, 525-528
immune detection type, 532-536
in cerebrovascular monitoring, 539-540
in kidney monitoring, 540
in pregnancy, 538-539
indirect, 536-538
multiple, 532, 535
populations targeted for, 529-531
prognosis and, 662-664
solid-phase immunoassays, 553
transplantation and, 612-613
transplantation and, 516, 611-631
- Antiphospholipid (Hughes) syndrome. *See also* Antiphospholipid antibodies.
asymptomatic, prognosis for, 661-662
catastrophic, 634-635, 666
chronic, treatment of, 635-640
classification criteria for, 499-505
aims of, 500, 502
clinical, 501
evaluation of, 503
for diagnosis, 504
laboratory, 501
limitations of, 500, 502
versus noncriteria features, 502-503
clinical features of, 507-524
cardiac, 512-514, 665
central nervous system, 507-511, 539-540, 665
cutaneous, 511-512
hematologic, 517-518, 639, 664
kidney, 514-516, 540, 665
obstetric. *See* Pregnancy, in antiphospholipid syndrome.
prognosis and, 664-666
pulmonary, 516-517, 633-634, 664-665
diagnosis of
classification criteria and, 504
definitive, 530
genetics of, 565-572
in pregnancy. *See* Pregnancy, in antiphospholipid syndrome.
in transplantation. *See* Transplantation.
long-term follow-up in, 662-664
prognosis in, 661-669
in asymptomatic state, 661-662
in pregnancy, 664
in systemic lupus erythematosus, 662
in thrombocytopenia, 664
long-term follow-up in, 662-664
versus clinical manifestations, 664-666
treatment of, 633-642
acute, 633-634
catastrophic, 634-635
chronic, 635-640
in pregnancy, 649-654
- Anxiety, in osteoporosis, 256-257
- Aorta
giant cell arteritis of, 681, 683
Takayasu's arteritis of
carotid artery bypass in, 714
epidemiology of, 733
- Apoptosis
in antiphospholipid antibody induction, 596-597, 626-627
inhibition of, in rheumatoid arthritis, 465-466
of neutrophils, in vasculitis, 892-893
- Arterial thrombosis, in antiphospholipid syndrome, treatment of, 634
- Arteritis
giant cell. *See* Giant cell (temporal) arteritis.
in polyarteritis nodosa. *See* Polyarteritis nodosa.
Takayasu's. *See* Takayasu's arteritis.
temporal. *See* Giant cell (temporal) arteritis.
- Arthritis
in drug-induced vasculitis, 854
osteoporosis and, estrogen effects on, 145-146, 153-154
rheumatoid. *See* Rheumatoid arthritis.
- Arthroscopy, for rheumatoid arthritis, synovial membrane characterization in, 374-376
- Aspirin
for antiphospholipid syndrome
chronic, 638

- Aspirin (*Continued*)
 in pregnancy, 649-652, 654
 for rheumatoid arthritis, 390, 393
- Atherosclerosis
 antiphospholipid antibodies and, 603-610
 clinical implications of, 607
 immune system involvement in, 605-607
 in antiphospholipid syndrome, 604-605
 in systemic lupus erythematosus, 603-604
 in rheumatoid arthritis, 287-288
 corticosteroid-induced, 398
- Athletes, bone mass in, 133
- Atovaquone, for *Pneumocystis carinii* prophylaxis, in Wegener's granulomatosis, 878
- Atrophie blanche, in polyarteritis nodosa, 681-682
- Autoimmune disorders
 ANCA-associated, 897-898
 etanercept-induced, 434-435
 infliximab-induced, 430-431
- Azathioprine
 for Behçet's disease, 772
 for Henoch-Schönlein purpura, 689
 for rheumatoid arthritis, carcinogenic effects of, 289-290
 for Wegener's granulomatosis, 872
- B lymphocytes, in rheumatoid arthritis
 pathogenesis, 335-353
 antibodies in, 339-343
 historical overview of, 335-337
 in synovial membrane infiltrates, 343-345
 TdT protein abnormalities in, 345-346
 treatment implications of, 346, 465
 versus normal B-lymphocyte development and selection, 337-339
- B7 molecule, inhibitors of, for rheumatoid arthritis, 452-453
- Bacterial antigens, in vasculitis, in 842-843
- Bactericidal/permeability-increasing protein, anti-neutrophil cytoplasmic antibodies directed to, 803, 805, 808
- Behçet's disease
 bruin in, 710
 central nervous system involvement in, 719-721
 erythema nodosum in, 719
 ocular manifestations of, 770-772
 retinal vasculitis in, 771-772
 thrombophlebitis in, 719
 uveitis in, 764
 vasculitis in, 743
- Biochemical markers, of bone turnover. *See* Bone, turnover of, biochemical markers for.
- Biologic agents
 for rheumatoid arthritis, 445-491. *See also specific agents.*
 methotrexate with, 422
 targets for
 adhesion molecules, 381, 463-464
 angiogenesis, 383, 463-464
 apoptosis, 465-466
 B lymphocytes, 465
 CD antigen, 447-449
 complement, 465
 costimulatory molecules, 320-322, 452-453
 cytokines, 454-464
 gene therapy, 467
 interferons, 458-459
 interleukin-1 receptor, 456-457
 interleukins, 454, 457-462
 major histocompatibility complex, 453-454
 metalloproteinases, 363-364, 466-467
 mitogen-activated protein kinases, 361, 438, 462-463
 nuclear factor-kB, 362-363, 383, 463
 T-cell receptor, 450-451
 T lymphocytes, 446-454
 vasculitis due to, 852
- Biopsy
 brain, in vasculitis, 717
 gastrocnemius muscle, in polyarteritis nodosa, 680
 in Churg-Strauss syndrome, 705
 in drug-induced vasculitis, 855
 kidney, in idiopathic rapidly progressive glomerulonephritis, 708
 muscle, in vasculitic neuropathy, 754, 756
 nerve, in vasculitic neuropathy, 754, 756
 skin, in Henoch-Schönlein purpura, 689-692
 sural nerve
 in Churg-Strauss syndrome, 705
 in polyarteritis nodosa, 680
 synovial, in rheumatoid arthritis, 374-376
 temporal artery, 683-687
- Bisphosphonates
 clinical uses of, 201
 for metastatic bone disease, 68, 70
 for osteoporosis, 168-169, 178, 197-214.
 See also specific drugs.
 approved agents for, 201-206
 chemistry of, 197-198
 comparison of, 207-208
 developmental, 207
 estrogens with, 152

- glucocorticoid-induced, 244-246
 in men, 37-38
 in rheumatoid arthritis, 293
 mechanisms of action of, 198-199
 nonapproved agents for, 206-207
 pharmacodynamics of, 199-200
 side effects of, 200-201
- Blood-nerve barrier, 752
- Blood pressure, measurement of, in giant cell arteritis, 683
- Body mass index, osteoporosis risk and, 31
- Bone
 formation of
 hormones in, 28
 over life cycle, 131-132
 loss of, in rheumatoid arthritis, 292-293, 295, 398
 metastasis to, bone turnover markers in, 65-70
 necrosis of, glucocorticoid-induced, 239-240
 remodeling of, over life cycle, 131-132
 remodeling transient of, 102-103
 resorption of, glucocorticoids in, 237-238
 strength of, in men versus women, 25-27
 turnover of
 biochemical markers for, 49-80, 166
 alkaline phosphatase, 50-52
 bone sialoprotein, 53-54
 calcitonin effects on, 191
 collagen propeptides, 51-53
 formation, 50-53
 hydroxylysine, 54-56
 hydroxyproline, 54-56
 hydroxyproline cross-links, 54, 56-57
 in bone disease treatment monitoring, 68, 70
 in breast cancer, 67
 in glucocorticoid-induced bone disease, 70-72
 in hyperparathyroidism, 62-64
 in malignant bone disease, 65, 67
 in multiple myeloma, 67-69
 in osteoporosis, 57-62
 in Paget's disease, 63
 in rheumatic disease, 72
 osteocalcin, 51-52
 resorption, 53-57
 tartrate-resistant acid phosphatase, 53-55
 estrogens in, 143-144
- Bone marrow transplantation, antiphospholipid antibodies and, 623-626
- Bone mass, peak, 34
- calcium importance in, 112
- in men versus women, 26
- Bone mineral density
 calcitonin effects on, 188-189
- calcium supplementation effects on, versus life cycle, 112-117
- exercise effects on, versus life cycle, 135-136
- genetic factors in, 10
- glucocorticoid effects on, 240-241
- growth hormone effects on, 218-221
- in children, 133-135
- in men versus women, 26
- in osteoporosis
 criteria for, 1-2
 preventive strategies based on, 15
 measurement of. *See* Densitometry.
 versus fracture risk, 2-3
 vitamin D effects on, 122
- Bone pain, calcitonin effects on, 192-193
- Bone sialoprotein, as marker for bone resorption, 53-54
- Brain, vasculitis of, 715-719
- biopsy in, 717
- versus amyloidosis, 718-719
- versus mass, 716
- Breast cancer, bone metastasis in, bone turnover markers in, 67
- Bruit, in Takayasu's arteritis, 710-711
- Buerger's disease
 causes of, 722
 digital ischemia in, 721
 pulse loss in, 711
 thrombophlebitis in, 721
 treatment of, 722-723
 ulcers in, 721-722
- C-reactive protein, in Takayasu's arteritis, 711
- Calcitonin, for osteoporosis, 169, 178, 187-196
 analgesic effects of, 192-193
 glucocorticoid-induced, 244, 879
 in combination therapy, 194
 in men, 38
 injectable, 188
 nasal, 188-193
 physiology of, 187
 preventive role of, 189
 resistance to, 193
 side effects of, 193
 steroid-induced, 192
 structure of, 187
- Calcium
 metabolism of, glucocorticoid effects on, 239
- osteoporosis and, 104-117
 absorption of, 104-105
 balance of, factors affecting, 106-107
 body distribution of, 104
 dietary guidelines for, 107-108
 food sources of, 107

Calcium (*Continued*)

- in elderly persons, 116-117
 - in lactation, 113-114
 - in menopause, 114-116
 - in pregnancy, 113-114
 - in rheumatoid arthritis, 293
 - metabolism of, 104
 - peak bone mineral density achievement, 112
 - studies of, 109-111
 - supplementation with, 109, 166-167
 - in calcitonin therapy, 193
 - in glucocorticoid therapy, 242-243
 - in men, 37
 - studies of, 109-111
 - types of, 109
 - versus life cycle, 112-117
 - urinary levels of, 106
 - versus life cycle, 112-117
- Cancer
- breast, bone metastasis in, bone turnover markers in, 67
 - in rheumatoid arthritis, 288-290, 294
 - infliximab-induced, 431
 - vasculitis related to, 743
- Carbon dioxide, diffusion capacity of, in microscopic polyangiitis, 706
- Cardiolipin, antibody to. *See* Anticardiolipin antibody.
- Cardiomyopathy, in Takayasu's arteritis, 713
- Cardiovascular disease, in rheumatoid arthritis, 285-288, 294
- Carotid artery bypass, in Takayasu's arteritis, 714
- Cartilage, antibodies to, in rheumatoid arthritis pathogenesis, 342-343
- Cathepsins, in rheumatoid arthritis pathogenesis, 364-366
- CD4 molecule, antibodies to, in rheumatoid arthritis, 447-449
- CD5 molecule, antibodies to, in rheumatoid arthritis, 449
- CD28 molecule, inhibitors of, for rheumatoid arthritis, 452-453
- CD40 molecule
- in rheumatoid arthritis pathogenesis, 321-322
 - in vasculitis pathogenesis, 894
 - inhibitors of, for rheumatoid arthritis, 452-453
- CD44 molecule, inhibitors of, for rheumatoid arthritis, 463-464
- CD80 molecule, in rheumatoid arthritis pathogenesis, 320-322
- CD86 molecule, in rheumatoid arthritis pathogenesis, 320-322
- CD154 molecule, inhibitors of, for rheumatoid arthritis, 452-453
- CDP 870 anti-tumor necrosis factor fragment, for rheumatoid arthritis, 436

Central nervous system

- antiphospholipid syndrome manifestations in, 507-511, 539-540, 665
 - Behçet's disease of, 719-721
 - isolated angiitis of, epidemiology of, 734
 - vasculitis of, 715-719
- Chemokines and chemokine receptors
- in T-lymphocyte migration, 318-319
 - inhibitors of, for rheumatoid arthritis, 464
- Chest radiography, in Wegener's granulomatosis, 695
- Chlorambucil
- for Behçet's disease, 771
 - for Wegener's granulomatosis, 876
- Chloroquine, for rheumatoid arthritis, 408
- Cholecalciferol (vitamin D₃), osteoporosis and
- metabolism of, 117-118
 - supplementation with, 123-124
- Churg-Strauss syndrome
- anti-neutrophil cytoplasmic antibodies in, 800, 804, 836, 888-889
 - biopsy in, 705
 - drug-induced, 852
 - eosinophil count in, 704
 - epidemiology of, 734, 737
 - immune complexes in, 839
 - kidney involvement in, 704-705
 - myocardial vasculitis in, 703
 - ocular manifestations of, 769-770
 - peripheral neuropathy in, 703
 - rheumatoid nodules in, 702-703
 - stages of, 702
 - treatment of, 704
 - versus hypereosinophil syndrome, 704
 - versus Wegener's granulomatosis, 702-703
- Claudication, jaw, in giant cell arteritis, 684-685
- Clodronate, for osteoporosis, 199, 206-207
- Coagulation cascade, antiphospholipid antibodies and, 573-586
- activated protein C regulation, 578-580
 - coagulation factor activation, 577-578
 - detection, 583
 - β_2 -glycoprotein. *See* β_2 -Glycoprotein.
 - inhibition, 580
 - membrane dynamics, 576-577, 580-582
 - platelets, 576
 - surface dynamics, 574-578, 580, 583
- Cocaine, vasculitis due to, 852-853
- Cogan's syndrome, 714-715
- bruit in, 710-711
 - ocular manifestations of, 775
- Cognitive dysfunction, in antiphospholipid syndrome, 509
- Collagen
- antibodies to, in rheumatoid arthritis pathogenesis, 342

- receptors for, in rheumatoid arthritis pathogenesis, 322-323
- Collagen propeptides, type I, as bone turnover marker, 51-53
- Collagenases, in rheumatoid arthritis pathogenesis, 363
- Complement
 - imbalance of, in cryoglobulinemic vasculitis, 709
 - inhibitors of, for rheumatoid arthritis, 465
- Computed tomography, quantitative, in bone density measurement, 83, 85, 88
- Cornea
 - inflammation of. *See* Keratitis.
 - ulcers of, in giant cell arteritis, 792
- Coronary artery disease, in antiphospholipid syndrome, 513-514
- Corticosteroids
 - for antiphospholipid syndrome, 650
 - for ocular manifestations, of vasculitis
 - Behçet's disease, 772
 - Churg-Strauss syndrome, 769-770
 - Cogan's syndrome, 775
 - giant cell arteritis, 777
 - keratitis, 764
 - optic neuritis, 766
 - optic neuropathy, 766
 - polyarteritis nodosa, 774
 - scleritis, 763
 - Takayasu's arteritis, 775
 - uveitis, 764-765
 - for polymyalgia rheumatica, 688-689
 - for rheumatoid arthritis, 389-403
 - adverse effects of, 395-398
 - cardiovascular, 287
 - gastrointestinal, 296
 - osteoporosis, 292-293, 295
 - disease progression and, 394-395
 - early, 407-410
 - evidence-based treatment strategy for, 398-400
 - in combinations, 422-423
 - radiologic progression and, 393-394
 - symptom relief and, 389-392
 - for vasculitis
 - Behçet's disease, 772
 - Churg-Strauss syndrome, 769-770
 - Cogan's syndrome, 775
 - drug-induced, 857
 - giant cell arteritis, 683-684, 777
 - Henoch-Schönlein purpura, 689
 - neuropathic, 756, 758
 - polyarteritis nodosa, 678, 774
 - Takayasu's arteritis, 714, 775
 - Wegener's granulomatosis, 698-699, 864-865
 - methotrexate with, 869-871
 - ocular manifestations, 769
 - osteoporosis due to, 235-253
 - assessment of, 240-241
 - bone resorption in, 237-238
 - bone turnover markers in, 70-72
 - calcitonin for, 192
 - clinical features of, 235-236
 - epidemiology of, 236-237
 - estrogen effects on, 150
 - hormonal factors in, 238-239
 - mineral metabolic abnormalities in, 239
 - muscular effects of, 240
 - osteonecrosis in, 239-240
 - parathyroid hormone in, 226-228, 247-248
 - pathophysiology of, 237-240
 - prevention and treatment of, 241-248, 879
 - Cortisol, in osteoporosis programming, 12
 - Cortisone, for rheumatoid arthritis, 390
 - Costimulatory molecules
 - in rheumatoid arthritis pathogenesis, 320-322
 - inhibitors of, for rheumatoid arthritis, 452-453
 - Cranial neuropathy, in vasculitis, 766-767
 - Crossmatching, with fluorescence-activated cell sorter, antiphospholipid antibody impact on, 622-623
 - Cryoglobulinemic vasculitis, 708-710
 - epidemiology of, 741
 - immune complexes in, 834
 - pearls and myths about, 708-710
 - Culture, in rheumatoid arthritis, 376
 - Cushing's disease, osteopenia in, bone turnover markers in, 70-72
 - Cyclophosphamide
 - for Behçet's disease, 772
 - for polyarteritis nodosa, 678
 - for vasculitic neuropathy, 756, 758
 - for Wegener's granulomatosis, 695-697, 769, 865-868, 878-879
 - Cyclosporine
 - for Behçet's disease, 772
 - for rheumatoid arthritis, 408-410, 420
 - for Wegener's granulomatosis, 876
 - neurotoxicity of, 720
 - Cysteine proteases, in rheumatoid arthritis pathogenesis, 364-366
 - Cystitis, cyclophosphamide-induced, 878-879
 - Cytokines
 - culture of, in rheumatoid arthritis, 376
 - in endothelial damage, in vasculitis, 895-896
 - in rheumatoid arthritis pathogenesis, 319-320, 326-327, 378-383
 - inhibitors of, for rheumatoid arthritis, 454-464
 - Cytomegalovirus infections, antiphospholipid antibody induction in, 555-558

- Cytotoxic T lymphocyte-associated clone 4, inhibitors of, for rheumatoid arthritis, 453
- Dalteparin, for antiphospholipid syndrome, in pregnancy, 654
- Dapsone, for *Pneumocystis carinii* prophylaxis, in Wegener's granulomatosis, 878
- D2E7 monoclonal antibody, in rheumatoid arthritis treatment, 435-436
- 7-Dehydrocholesterol, as vitamin D precursor, 117-118
- Dehydroepiandrosterone, deficiency of, osteoporosis in, 30
- Dementia, in antiphospholipid syndrome, 509
- Densitometry, 81-100, 166
 - central versus peripheral, 95-96
 - in children, 99, 133-135
 - in fracture risk assessment, 94-95
 - in glucocorticoid-induced osteoporosis, 240-241
 - in skeletal change monitoring, 95
 - of hip, 98
 - peripheral versus central, 95-96
 - results of, versus normative data, 92-94
 - special scans in, 96-99
 - techniques for, 81-91
 - comparison of, 91-92
 - computed tomography, 83, 85, 88
 - dual energy, 82-84, 86-87, 98-99
 - radiation dose for, 90-91
 - single energy, 82
 - terminology of, 81-82
 - ultrasonography, 88-90
 - uses of, 91-99
 - vertebral morphometry scans in, 97
- Dental health, estrogen effects on, 149
- Depression, in osteoporosis, 258-259
- Dermatomyositis, vasculitis in, 743
- Diabetes mellitus, amyotrophy in, 756-757
- Dialysis, in Wegener's granulomatosis, 882
- Digital ischemia, in Buerger's disease, 721
- 1,25-Dihydroxyvitamin D (calcitriol), osteoporosis and deficiency of, 121
- metabolism of, 117-119
- supplementation with, 122, 124-125
- Diplopia, in giant cell arteritis, 789-790
- Direct immunofluorescence test, in Henoch-Schönlein purpura, 689-692
- Disease-modifying antirheumatic drugs, for rheumatoid arthritis, combination, 415-426
 - biologic agents in, 422
 - in early disease, 417-419
 - in methotrexate failure, 419-420
 - indications for, 417
 - nonconventional, 422-423
 - patient selection for, 423
 - triple, 420-421
- Disintegrins, in rheumatoid arthritis pathogenesis, 364
- DMARDs. *See* Disease-modifying antirheumatic drugs.
- dnaj heat shock protein, antibodies to, in rheumatoid arthritis, 341
- Doxycycline, for rheumatoid arthritis, 423
- Drugs
 - abuse of, vasculitis due to, 852-853
 - osteoporosis due to, in men, 32
 - vasculitis due to. *See* Vasculitis, drug-induced.
- Dual energy densitometry, 82-84, 86-87, 98-99
- Dyslipidemia, in rheumatoid arthritis, 285-288
- Ear complications, in Wegener's granulomatosis, 879-880
- Eicosanoid metabolism, endothelial, antiphospholipid antibodies and, 595-596
- Elderly persons
 - calcium supplementation for, 116-117
 - exercise for, 137-138
- Electromyography, in Churg-Strauss syndrome, 705
- Embolism, pulmonary, in antiphospholipid syndrome, 516, 633-634, 664-665
- Endosomes, late, endothelial, antiphospholipid antibody interactions with, 597
- Endothelial cells
 - anti-neutrophil cytoplasmic antibodies and, 820-822, 893-894, 897
 - antibodies to, in vasculitis, 834-835, 842, 893-894
- Endothelins, antiphospholipid antibody interactions with, 596
- Endothelium, antiphospholipid antibody interactions with, 587-602
 - annexin V in, 595
 - apoptosis, 596-597
 - eicosanoid metabolism and, 595-596
 - β_2 -glycoprotein cofactor in, 589-591
 - late endosome, 597
 - mechanisms of, 593-594
 - proadhesive and proinflammatory phenotype induction in, 591-593
 - procoagulant phenotype and, 594-595
 - versus anatomic district, 597-598
 - vessel tone regulation and, 596
- Enoxaparin, for antiphospholipid syndrome, in pregnancy, 654

- Environmental factors
 in giant cell arteritis, 731
 in Henoch-Schönlein purpura, 740
 in osteoporosis, 10-12
 in rheumatoid arthritis, 276-277
- Enzyme immunoassays, for anti-neutrophil cytoplasmic antibodies, 805-807
- Enzyme-linked immunosorbent assay, for antiphospholipid antibodies, 533, 553
- Eosinophilia
 in Churg-Strauss syndrome, 702, 704
 in drug-induced vasculitis, 855
- Episcleritis, in vasculitis, 761-763
- Ergocalciferol (vitamin D₂), osteoporosis and
 metabolism of, 117-118
 supplementation with, 123-124
- Erythema nodosum, in Behçet's disease, 719
- Erythrocyte sedimentation rate
 in giant cell arteritis, 685-686
 in Takayasu's arteritis, 711
- Escherichia coli* heat shock protein, antibodies to, in rheumatoid arthritis, 341
- Estrogens
 for osteoporosis, 143-162, 167-168
 androgens with, 150-151
 arthritis and, 145-146, 153-154
 benefits of, 152-155
 dental aspects of, 149
 disadvantages of, 153
 exercise with, 152
 fracture risk and, 28-30, 144-145
 glucocorticoid-induced, 243-244
 indications for, 147-148
 initiation of, 148-149
 low-dose, 151
 nutritional supplements with, 152
 physiology of, 143-144
 products for, 146-147
 progesterone with, 150
 selective estrogen receptor modulators with, 151-152
 rheumatoid arthritis and, 277, 287-288
- Etanercept
 antibodies and autoantibodies to, 434-435
 for rheumatoid arthritis, 410, 422, 432-435
 for Wegener's granulomatosis, 877
- Ethnic factors, in osteoporosis, 9-10
 in men, 21-22
- Etidronate, for osteoporosis, 201-202, 206
 glucocorticoid-induced, 245-246
 in men, 37-38
 mechanism of action of, 198-199
 pharmacodynamics of, 199-200
 side effects of, 200
- Evans' syndrome, 517
- Exercise, for osteoporosis prevention and treatment, 31-32, 131-141
 amenorrhea and, 137
 bone physiology and, 131-135
 estrogens with, 152
 goals of, 138-139
 gymnastics and, 137
 in older people, 137-138
 swimming, 137
 versus life cycle, 135-136
- Extracellular matrix proteins, in rheumatoid arthritis pathogenesis, 322-323, 363-366
- Extracellular signal-regulated kinase, in rheumatoid arthritis pathogenesis, 361
- Eye, vasculitis manifestations in. See Ocular manifestations, of vasculitis.
- Factor V Leiden, antiphospholipid syndrome and, 570
- Falls
 in men versus women, 27
 prevention of, 15, 36-37, 180
 exercise in, 137-138
 risk factors for, in men, 33
- Fever, in giant cell arteritis, 685
- Fibronectin receptors, in rheumatoid arthritis pathogenesis, 322-323
- FK506 (tacrolimus)
 for Wegener's granulomatosis, 876
 neurotoxicity of, 720
- Fluorescence-activated cell sorter, for crossmatching, antiphospholipid antibody impact on, 622-623
- Fluoride supplementation, in osteoporosis, 38, 246-247
- Forearm
 densitometry of, quantitative computed tomography in, 88
 fractures of, in osteoporosis
 epidemiology of, 6, 25
 morbidity in, 14
- Fractures
 in osteoporosis. See also specific bones.
 bone density and, 2-3
 calcitonin effects on, 188-191
 clustering of, 6-7
 consequences of, 163-164
 epidemiology of, 2-7, 22-25
 geographical factors in, 9-10
 morbidity in, 13-14
 mortality in, 12-13
 occurrence of, 3-7
 prediction of
 bone turnover markers in, 61-62
 densitometry in, 94-95
 prevention of, 14-15
 risk factors for

Fractures (*Continued*)

- estrogen deficiency, 144-145
 - in men, 27-33
 - time trends in, 7-9
 - treatment effects on, 177-180
 - in rheumatoid arthritis, 292-293, 295
- Free radicals, in endothelial damage, 891

Gangrene, in antiphospholipid syndrome, 512, 665-666

Gastrocnemius muscle, biopsy of, in polyarteritis nodosa, 680

Gastrointestinal disease, in rheumatoid arthritis, 293, 295-296

Gelatinases, in rheumatoid arthritis pathogenesis, 363-364

Gene therapy, for rheumatoid arthritis, 467

Genetic factors

- in antiphospholipid syndrome, 565-572
- β_2 -glycoprotein, 565-568
- human leukocyte antigen genotypes and, 568-569
- risk factors and, 568-570
- variance in, 569-570
- in giant cell arteritis, 730-731
- in Kawasaki disease, 738-739
- in osteoporosis, 10
- in rheumatoid arthritis, 275-276, 305-315
- in Takayasu's arteritis, 732-733

Giant cell (temporal) arteritis

- aortic, 681, 683
- blood pressure measurement in, 683
- bruit in, 710
- environmental factors in, 731
- epidemiology of, 730-732
- genetic factors in, 730-731
- pulse loss in, 711
- treatment of, 687-688
- vessels affected in, 681, 683
- visual manifestations of, 775-777, 781-797

797

- corneal ulceration, 792
- diplopia, 789-790
- hallucinations, 789
- ischemic optic neuropathy, 776, 784-787

- ocular hypotony, 791
- ocular ischemic syndrome, 790-791
- pupillary disturbances, 790
- retinal artery occlusion, 782-784
- visual field defects, 787-789
- visual loss, 781-782

Glomerular basement membrane, antibodies to

- in microscopic polyangiitis, 707
- in vasculitis, 834-835

Glomerulonephritis

- idiopathic rapidly progressive, 707-708, 896-897

necrotizing crescentic progressive, anti-neutrophil cytoplasmic antibodies in, 836-840, 842, 892

pauci-immune, 837-838

Glucocorticoids. *See* Corticosteroids.

 β_2 -Glycoprotein

antibodies to

- induction of, 554-556, 558-559
- tests for, 532-534, 537

antiphospholipid antibody interactions with

- cofactor function of, 589
- in endothelium, 589-591
- deficiency of, genetics of, 567-568
- in antiphospholipid syndrome
- atherosclerosis and, 604-605
- genetics of, 565-568
- polymorphisms of, 565-567
- in coagulation, 582-583

Gold salts, for rheumatoid arthritis, versus prednisolone, 391

Granulocyte colony-stimulating factor, in neutropenia, in Wegener's granulomatosis, 879

Granulomatosis, Wegener's. *See* Wegener's granulomatosis.

Growth hormone

- deficiency of, osteoporosis in, in men, 32
- for osteoporosis treatment, 217-222

Gymnasts, bone status of, 137

Hallucinations, visual, in giant cell arteritis, 789

Headache

- in giant cell arteritis, 685
- migraine, anticardiolipin antibodies and, 508-509

Hearing loss, in antiphospholipid syndrome, 511

Heart

- antiphospholipid syndrome manifestations in, 512-514, 665
- transplantation of, antiphospholipid antibodies and, 620-621

Heat shock protein, antibodies to, in rheumatoid arthritis, 341

Hematuria, in Wegener's granulomatosis, 694-695

Hemolytic anemia, in antiphospholipid syndrome, 517-518

Hemorrhage

- alveolar, in antiphospholipid syndrome, 517
- pulmonary, in microscopic polyangiitis, 706
- splinter, in Buerger's disease, 722
- subungual, in antiphospholipid syndrome, 512

- Henoch-Schönlein purpura
 epidemiology of, 739-741
 immune complexes in, 834
 immunoglobulin A deposition in, 694
 immunoglobulin A paraproteinemia in, 692-693
 intussusceptions in, 693
 prolonged standing in, 693
 renal involvement in, 693
 skin biopsy in, 689-692
 treatment of, 689
 versus microscopic polyangiitis, 692
- Heparin, for antiphospholipid syndrome
 acute, 633-634
 chronic, 639
 in pregnancy, 651-654
- Hepatitis B, vasculitic neuropathy in, 757-758
- Hepatitis C
 antibodies in, 709
 antiphospholipid antibody induction in, 559, 616
 vasculitic neuropathy in, 757-758
- Hip
 densitometry of, 98
 fractures of, in osteoporosis
 calcium absorption and, 104-105
 epidemiology of, 4-5, 7-9, 22-24
 ethnic factors in, 9-10
 morbidity in, 14
 mortality in, 13
 prediction of, 89-90, 94
 risk of, in estrogen deficiency, 144-145
 treatment effects on, 177-180
 with other fractures, 6-7
- Hormones. *See also specific hormones.*
 disorders of, osteoporosis due to, in men, 32-33
 in osteoporosis
 fracture risk and, 27-31
 in early programming, 11-12
- Horner's syndrome, in giant cell arteritis, 790
- hprt* gene mutations, in rheumatoid arthritis, 360
- Hughes syndrome. *See* Antiphospholipid (Hughes) syndrome.
- Human leukocyte antigens
 antiphospholipid antibodies and, 568-569
 in Henoch-Schönlein purpura, 740
 in rheumatoid arthritis susceptibility, 305-315
 in Takayasu's arteritis, 732-733
 in vasculitis, 735
- Humeral fractures, in osteoporosis, epidemiology of, 6
- Hyaluronan receptor, inhibitors of, for rheumatoid arthritis, 463-464
- Hydroxychloroquine
 for antiphospholipid syndrome, 639-640
 for rheumatoid arthritis, 407, 410
 in combinations, 418, 420-421
- Hydroxylysine, as bone turnover marker, 54-56
- Hydroxyproline, as bone turnover marker, 54-56
- Hydroxypyridinium cross-links, as bone turnover markers, 54, 56-57
- Hypercalciuria, osteoporosis in, 106
- Hypereosinophilic syndrome, versus Churg-Strauss syndrome, 704
- Hyperparathyroidism
 bone turnover markers in, 62-64
 secondary, senile osteoporosis in, 123
- Hypersensitivity vasculitis. *See also* Vasculitis, drug-induced.
 epidemiology of, 741
- Hypertension, in antiphospholipid syndrome
 pulmonary, 516-517, 530-531, 664-665
 systemic, 514-515
- Hypogonadism, osteoporosis risk in, 28-30
- Hypopyon, in Behçet's disease, 771
- Hypotony, ocular, in giant cell arteritis, 791
- Idiopathic rapidly progressive glomerulonephritis, 707-708, 896-897
- Immobilization, osteoporosis risk in, 31-32, 132
- Immune complexes, in vasculitis, anti-neutrophil cytoplasmic antibodies and, 833-834, 838-843
- Immune globulin
 for antiphospholipid syndrome, 635
 in pregnancy, 653
 intravenous, for Wegener's granulomatosis, 875-876
- Immune system, in atherosclerosis development, 605-607
- Immunodeficiency, in rheumatoid arthritis infections in, 290-292, 295
 treatment-related, 288-290
- Immunofluorescent test, for anti-neutrophil cytoplasmic antibodies, 802-805
- Immunoglobulin(s)
 Fc portion of, antibodies to. *See* Rheumatoid factor.
 in rheumatoid arthritis pathogenesis, 345-346, 465
 normal development and selection of, 337-339
 structure of, 337
- Immunoglobulin A, in Henoch-Schönlein purpura, 692-694
- Immunosuppressive therapy
 for antiphospholipid syndrome, in pregnancy, 653

- Immunosuppressive therapy (*Continued*)
 for Churg-Strauss syndrome, 704
 for drug-induced vasculitis, 857
 for Henoch-Schönlein purpura, 689
 for scleritis, in vasculitis, 763
 for vasculitic neuropathy, 758
 for Wegener's granulomatosis, 769
 Indomethacin, for scleritis, in vasculitis, 763
 Infections
 antiphospholipid antibody induction in, 555-559
 in rheumatoid arthritis, 276-277, 290-292, 295, 397
 etanercept-related, 434
 infliximab-related, 430
 tumor necrosis factor- α blocker-related, 438
 vasculitis related to, 735, 743, 842-843
 Henoch-Schönlein, 739-740
 Kawasaki disease, 739
 Wegener's granulomatosis, 700-702
 Inflammation
 in atherosclerosis development, 605-607
 in rheumatoid arthritis, pathogenesis of.
 See Rheumatoid arthritis, pathogenesis of.
 Infliximab, for rheumatoid arthritis, 410, 428-432
 antibodies and autoantibodies to, 430-431
 methotrexate with, 422
 Insulin-like growth factor 1
 deficiency of, osteoporosis in, in men, 32
 for osteoporosis prevention and treatment, 221-222
 Integrins, inhibition of, in rheumatoid arthritis, 464
 Intercellular adhesion molecule-1,
 inhibitors of, for rheumatoid arthritis, 381, 463
 Interferon(s)
 for rheumatoid arthritis treatment, 458-459
 in rheumatoid arthritis pathogenesis, 319-320
 vasculitis due to, 852
 Interleukin(s)
 in rheumatoid arthritis pathogenesis, 319-320, 326-327, 378-383
 inhibitors of, for rheumatoid arthritis, 454, 462
 Interleukin-1 receptor antagonists, in rheumatoid arthritis, 456-457
 Interleukin-2 receptor, antibodies to, in rheumatoid arthritis, 449-450
 Interleukin-4, for rheumatoid arthritis, 461
 Interleukin-6, inhibitors of, for rheumatoid arthritis, 459
 Interleukin-8
 in neutrophil sequestration, 890-891
 inhibitors of, for rheumatoid arthritis, 464
 Interleukin-10, for rheumatoid arthritis, 379, 459-461
 Interleukin-11, inhibitors of, for rheumatoid arthritis, 462
 Interstitial keratitis, in vasculitis, 763-764
 in Cogan's syndrome, 775
 Intussusception, in Henoch-Schönlein purpura, 693
 Ischemia, of optic nerve, in giant cell arteritis, 776, 784-787
 Jaw claudication, in giant cell arteritis, 684-685
 Jun N-terminal kinase, in rheumatoid arthritis pathogenesis, 361
 Kawasaki disease, epidemiology of, 738-739
 Keratitis
 in Cogan's syndrome, 714-715, 775
 in vasculitis, 763-764
 Keratoconjunctivitis sicca, in rheumatoid arthritis, 773
 Kidney
 biopsy of, in idiopathic rapidly progressive glomerulonephritis, 708
 disorders of. *See also* Glomerulonephritis.
 in antiphospholipid syndrome, 514-516
 monitoring of, 540
 prognosis in, 665
 in Churg-Strauss syndrome, 704-705
 in Henoch-Schönlein purpura, 693
 in microscopic polyangiitis, 706
 in Wegener's granulomatosis, 698-700, 882
 transplantation of, in Wegener's granulomatosis, 699-700
 vasculitis of, 707-708
 cryoglobulinemic, 710
 L.A. *See* Lupus anticoagulant.
 Lactation, bone mineral density in, 113-114
 Laser therapy, for subglottic stenosis, in Wegener's granulomatosis, 700
 Late endosomes, endothelial, antiphospholipid antibody interactions with, 597
 Leflunomide
 for rheumatoid arthritis, 410
 methotrexate with, 421

- for Wegener's granulomatosis, 875
- Left ventricular assist devices, thrombosis with, antiphospholipid antibodies and, 620-621
- Lenercept, for rheumatoid arthritis, 436-437
- Leukemia, in rheumatoid arthritis, 288-290
- Leukocytoclastic angiitis, cutaneous, 741
- Leukocytoclastic vasculitis, immune complexes in, 834
- Leukotrienes, inhibitors of, vasculitis due to, 852
- Lifestyle changes, in osteoporosis prevention, 15, 36-37, 180
- Lipids, protein interactions with, in coagulation cascade, 576-577
- Lipoprotein profile, in rheumatoid arthritis, 285-288
- Livedo reticularis, in antiphospholipid syndrome, 511
- Liver
 - dysfunction of, in bone marrow transplantation, 625
 - transplantation of, antiphospholipid antibodies and, 619-620
- Lumbar puncture, in central nervous system vasculitis, 715-716
- Lumbosacral plexus, vasculitis affecting, 756, 758
- Lung
 - antiphospholipid syndrome manifestations in, 516-517, 530-531, 664-665
 - hemorrhage of, in microscopic polyangiitis, 706
 - polyarteritis nodosa effects on, 678
 - Wegener's granulomatosis manifestations in, 700
- Lupus anticoagulant
 - in antiphospholipid syndrome, 501
 - prognosis and, 662-663
 - in transplantation
 - bone marrow, 623
 - heart, 621-622
 - kidney, 613-614, 617
 - tests for, 536, 552-553
- Lymphoid organogenesis, in rheumatoid arthritis pathogenesis, 323-326
- Lymphoma, in rheumatoid arthritis, 288-290
- Lymphoproliferative disorders, in rheumatoid arthritis, 288-290
 - etanercept-induced, 435
 - infliximab-induced, 431
- Macrophages, anti-neutrophil cytoplasmic antibodies proinflammatory effects on, 822-823, 896-897
- Magnetic resonance imaging
 - in central nervous system vasculitis, 715-717
 - in rheumatoid arthritis, 374-375
- Major histocompatibility complex antagonists of, in rheumatoid arthritis, 453-454
 - in rheumatoid arthritis susceptibility, 305-315
- Markers, of bone turnover. *See* Bone, turnover of, biochemical markers for.
- Matricellular proteins, in rheumatoid arthritis pathogenesis, 322-323
- Medroxyprogesterone, for osteoporosis, 151
- Men, osteoporosis in, 19-47
 - definition of, 19-20
 - evaluation of, 35-36
 - fractures in
 - epidemiology of, 22-25
 - risk factors for, 27-35
 - versus women, 25-27
 - prevalence of, 20-22
 - prevention of, 34-35
 - treatment of, 33-39, 224-226
- Metalloproteinases, inhibitors of, for rheumatoid arthritis, 363-364, 466-467
- Metastasis, to bone, bone turnover markers in, 65-70
- Methamphetamine, vasculitis due to, 852
- Methotrexate
 - for rheumatoid arthritis
 - carcinogenic effects of, 288-289
 - cardiovascular effects of, 287
 - early, 406-410
 - immunosuppressive effects of, 290-292
 - in combination, tumor necrosis factor-a blockade, 437-438
 - in combinations, 415-426
 - biologic agents, 422
 - corticosteroids, 422-423
 - cyclosporine, 420
 - etanercept, 422, 433-434
 - hydroxychloroquine, 418, 420-421
 - infliximab, 422, 429-430
 - leflunomide, 421
 - sulfasalazine, 417-418, 420-421
 - triple, 420-421
 - tumor necrosis factor-a blockade, 422
 - suboptimal response to, 419-420
 - for Wegener's granulomatosis, 869-873
- Microscopic polyangiitis
 - anti-endothelial cell antibody antigens in, 842
 - anti-neutrophil cytoplasmic antibodies in, 800, 836, 842, 888-889
 - antibodies in, 707
 - epidemiology of, 734-737
 - kidney involvement in, 706
 - prognosis for, 705-706
 - pulmonary hemorrhage in, 706

- Microscopic polyangiitis (*Continued*)
 versus Henoch-Schönlein purpura, 692
 vessels affected by, 705-706
- Migraine, anticardiolipin antibodies and, 508-509
- Minocycline, for rheumatoid arthritis, 423, 466-467
- Mitogen-activated protein kinases
 in rheumatoid arthritis pathogenesis, 361, 438
 inhibitors of, for rheumatoid arthritis, 462-463
- Molecular mimicry, in antiphospholipid antibody induction, 556-559
- Monoclonal antibodies, for rheumatoid arthritis
 adhesion molecule, 463-464
 CD4 antigen, 447-450
 complement, 465
 tumor necrosis factor- α . *See also* Infliximab.
 human and humanized, 435-436
 polyethylene glycolated, 436
- Monocytes, anti-neutrophil cytoplasmic antibodies proinflammatory effects on, 822-823, 889, 894, 896-897
- Mononeuritis multiplex
 in polyarteritis nodosa, 679
 in vasculitis, 754-755
- Multiple myeloma
 bone turnover markers in, 67-69
 in rheumatoid arthritis, 288-290
- Multiple sclerosis, versus antiphospholipid syndrome, 509-510
- Muscles
 biopsy of, in vasculitic neuropathy, 754, 756
 glucocorticoid effects on, 240-241
- Mutation, somatic, in rheumatoid arthritis, 357-360
- Mycophenolate mofetil, for Wegener's granulomatosis, 875
- Myeloma, multiple, bone turnover markers in, 67-69
- Myelopathy, transverse, in antiphospholipid syndrome, 665
- Myeloperoxidase
 anti-neutrophil cytoplasmic antibodies directed to. *See* Anti-neutrophil cytoplasmic antibodies, myeloperoxidase-directed.
 in endothelial damage, 891-892
- Myocardial infarction, in rheumatoid arthritis, 285
- Myocardial ischemia, in antiphospholipid syndrome, 665
- Myocardium, Churg-Strauss syndrome effects on, 703
- Nailfold infarction, in rheumatoid vasculitis, 724
- Necrosis, of bone, glucocorticoid-induced, 239-240
- Necrotizing scleritis, in Wegener's granulomatosis, 762
- Neovascularization, inhibitors of, for rheumatoid arthritis, 383, 463-464
- Nephropathy, in antiphospholipid syndrome, 514-516, 540, 665
- Nerve(s)
 biopsy of, in vasculitic neuropathy, 754, 756
 vascular organization of, 751-752
- Nerve conduction studies
 in Churg-Strauss syndrome, 705
 in vasculitis, 755
- Neuritis, optic, in vasculitis, 766
- Neurologic disorders
 in antiphospholipid syndrome, 507-511, 665
 in Behçet's disease, 719-721
 in central nervous system vasculitis, 715-719
- Neuropathy
 in Churg-Strauss syndrome, 703
 in giant cell arteritis, 776, 784-787
 in polyarteritis nodosa, 679
 optic, in vasculitis, 766, 776, 784-787
 vasculitic, 751-760
 anatomic considerations in, 751-752
 causes of, 751
 clinical features of, 754-755
 histology of, 752-754
 in diabetes mellitus, 756-757
 in hepatitis, 757-758
 of peripheral nerves, 756-758
 treatment of, 758
- Neutropenia, in Wegener's granulomatosis, 697, 879
- Neutrophil(s), anti-neutrophil cytoplasmic antibody interactions with
 adhesion of, 890
 endothelial injury in, 890-892
 fate of, 892-893
 in early lesions, 888-889
 in late lesions, 889
 priming of, 889-890
 proinflammatory effects of, 817-820
- Nitric oxide, in endothelial damage, 891-892
- Nodule(s)
 in scleritis, 762
 rheumatoid, in Churg-Strauss syndrome, 702-703
- Nonsteroidal anti-inflammatory drugs, for rheumatoid arthritis
 cardiovascular effects of, 287
 gastrointestinal effects of, 293, 295-296
- Nose, Wegener's granulomatosis manifestations in, 879-880

- Nuclear factor-kB, inhibitors of, for
rheumatoid arthritis, 362-363, 383, 463
- Ocular ischemic syndrome, in giant cell
arteritis, 790
- Ocular manifestations, of vasculitis,
761-779
in Behçet's disease, 770-772
in Churg-Strauss syndrome, 769-770
in Cogan's syndrome, 714-715, 775
in connective tissue disorders, 772-773
in giant cell arteritis, 775-777
in polyarteritis nodosa, 773-774
in Takayasu's arteritis, 774-775
in Wegener's granulomatosis, 768-769
ischemic optic neuropathy, 766
keratitis, 763-764
neuro-ophthalmologic, 766-767
ophthalmoplegia, 766-767
optic neuritis, 766
orbital, 767, 881-882
retinal. *See* Retinopathy, in vasculitis.
scleritis, 761-763
uveitis, 764-765
- Ophthalmoplegia, in vasculitis, 766-767
- Optic neuritis, in vasculitis, 766
- Optic neuropathy, in vasculitis, 766
- Oral contraceptives, rheumatoid arthritis
and, 277
- Orbital manifestations, of vasculitis, 767
giant cell arteritis, 790-791
Wegener's granulomatosis, 768-769,
881-882
- Osteoarthritis, osteoporosis and, 145
- Osteocalcin, as marker for bone formation,
51-52
- Osteoclasts, glucocorticoid effects on,
237-238
- Osteolysis, metastatic, bone turnover
markers in, 65-70
- Osteonecrosis, glucocorticoid-induced,
239-240
- Osteoporosis
alcohol use and, 31
bone turnover markers in, 49-80, 166,
191
calcium and. *See* Calcium, osteoporosis
and.
clinical features of, glucocorticoid-in-
duced, 235-236
definition of, 1-2, 165-166
in men, 19-20
densitometry in. *See* Densitometry.
economic impact of, 3
environmental factors in, 10-12
epidemiology of, 1-18
early environmental influences, 10-12
fractures, 2-10
genetic, 10
glucocorticoid-induced, 236-237
in men, 20-22
morbidity, 13-14
mortality, 12-13
ethnic factors in, 9-10, 21-22
evaluation of
biochemical markers in, 57-59
glucocorticoid-induced, 240-241
in men, 35-36
fractures in. *See* Fractures, in osteoporosis.
genetic factors in, 10
glucocorticoid-induced. *See* Corticoste-
roids, osteoporosis due to.
in men, 19-47, 224-226
in nutritional deficiencies, 101-103
in rheumatic disease, 164-165
in rheumatoid arthritis. *See* Rheumatoid
arthritis, osteoporosis in.
latency of, 164
nonskeletal consequences of, 255-262
psychologic, 256-259
social, 259-260
pathophysiology of, 163
glucocorticoid-induced, 237-240
prevalence of, in men, 20-22
prevention and treatment of, 14-15, 163-
185
anabolic agents in, 215-233, 246-247
bisphosphonates in. *See* Bisphospho-
nates, for osteoporosis.
calcitonin in. *See* Calcitonin.
calcium in. *See* Calcium, osteoporosis
and.
clinical trials of, 178-180
combined antiresorptive agents in,
175-176
dietary supplementation in, 180-181.
See also Calcium; Vitamin D.
estrogens in. *See* Estrogens, for osteo-
porosis.
exercise in, 31-32, 131-141
fluoride in, 38, 246-247
fracture rate after, 177-180
glucocorticoid-induced, 150, 192, 226-
228, 879
growth hormone in, 217-221
in men, 33-39, 224-226
indications for, 165-166
insulin-like growth factor 1 in, 221-
222
lifestyle changes in, 15, 36-37, 180
methods for, 166-167
need for, 163-166
parathyroid hormone in, 222-231,
247-248
progesterone in, 243-244
safety issues in, 228-229
selective estrogen receptor modulators
in, 151-152, 169-175, 178

Osteoporosis (*Continued*)

- testosterone in, 244
 - vitamin D in. *See* Vitamin D, osteoporosis and.
 - psychologic impact of, 256-259
 - risk factors for, in men, 27-35
 - senile (type II), vitamin D in, 123
 - smoking and, 31
 - social impact of, 259-260
 - treatment of. *See* Osteoporosis, prevention and treatment of.
 - vitamin D and. *See* Vitamin D, osteoporosis and.
- Osteoprotegerin, in rheumatoid arthritis pathogenesis, 326
- Oxygen free radicals, in endothelial damage, 891
- p38 protein, in rheumatoid arthritis pathogenesis, 361
- p53 tumor suppressor gene, mutations of, in rheumatoid arthritis, 357-360
- Paget's disease of bone, bone turnover markers in, 63
- Pain
- abdominal, in Henoch-Schönlein purpura, 693
 - back, in Takayasu's arteritis, 710
 - bone, calcitonin effects on, 192-193
 - ocular, in scleritis, 762
- Pamidronate, for osteoporosis, 202, 207
- glucocorticoid-induced, 245
 - side effects of, 200-201
- Panuveitis, in vasculitis, 764-765
- Paraproteinemia, immunoglobulin A, in Henoch-Schönlein purpura, 692-693
- Parathyroid hormone
- excess of
 - bone turnover markers in, 62-64
 - senile osteoporosis in, 123
 - in calcium metabolism, 117
 - in osteoporosis, 222-231, 247-248
 - levels of, glucocorticoid effects on, 239
- Pediatric patients
- bone densitometry in, 99
 - calcium supplementation in, 112-113
 - physical activity in, bone status and, 133-135
- Pelvic fractures, in osteoporosis, epidemiology of, 6
- Pentamidine, for *Pneumocystis carinii* prophylaxis, in Wegener's granulomatosis, 878
- Peptic ulcer disease, in rheumatoid arthritis, 296, 397
- Peripheral nerves, vascular organization of, 751-752
- Peripheral ulcerative keratitis, in vasculitis, 763-764

Phospholipids

- antibodies to. *See* Antiphospholipid antibodies; Antiphospholipid (Hughes) syndrome.
 - protein interactions with, in coagulation cascade, 576-577
- Plasmapheresis
- for antiphospholipid syndrome, 635
 - for Wegener's granulomatosis, 875-876
- Platelets, in coagulation cascade, 576
- Pneumocystis carinii* pneumonia,
- prophylaxis for, in Wegener's granulomatosis, 697, 877-878
- Polyangiitis, microscopic. *See* Microscopic polyangiitis.
- Polyarteritis nodosa
- atrophie blanche in, 681-682
 - epidemiology of, 734-737
 - gastrocnemius muscle biopsy in, 680
 - lung involvement in, 678
 - mononeuritis multiplex in, 679
 - ocular manifestations of, 773-774
 - sural nerve biopsy in, 680
 - treatment of, 678
 - venous sparing in, 681
 - visceral abdominal angiography in, 680-681
- Polyethylene glycol
- in monoclonal antibody modification, for rheumatoid arthritis treatment, 436
 - in soluble tumor necrosis factor receptor type I modification, for rheumatoid arthritis treatment, 437
- Polymyalgia rheumatica, 688-689
- Polymyositis, vasculitis in, 743
- Pre-eclampsia, in antiphospholipid syndrome, 646, 649
- Prednisolone
- for antiphospholipid syndrome, in pregnancy, 650
 - for rheumatoid arthritis, 390-392
 - early, 407-410
 - in combinations, 417-418, 423
 - radiologic progression and, 393-394
 - withdrawal from, 400
- Prednisone
- for Churg-Strauss syndrome, 769-770
 - for giant cell arteritis, 777
 - for polyarteritis nodosa, 774
 - for polymyalgia rheumatica, 688-689
 - for rheumatoid arthritis, 407
 - osteoporosis induced by, 292-293, 295
 - for scleritis, in vasculitis, 763
 - for uveitis, in vasculitis, 765
 - for Wegener's granulomatosis, 865
 - methotrexate with, 869-871
- Pregnancy
- bone mineral density in, 113-114
 - in antiphospholipid syndrome, 501, 643-659

- antibody tests in, 535, 538-539
 - early failure of, 645
 - effects on pregnancy, 644-648, 664
 - effects on syndrome, 643-644
 - fetal risks in, 646-647, 664
 - late complications of, 645
 - maternal risks in, 645-646
 - morbidity in, 664
 - placental pathology in, 646
 - treatment of, 647-654
 - pharmacologic, 649-653
 - preconception, 647, 649
 - with antibodies alone, 654
 - with previous thrombosis, 653-654
 - with recurrent fetal loss, 654
 - in Takayasu's arteritis, 713
- Progesterone, for osteoporosis, 150, 243-244
- Programming, of osteoporosis, 11-12
- Proptosis, in vasculitis, 767
- Protein(s)
 - excess intake of, calcium balance and, 107
 - lipid interactions with, in coagulation cascade, 576-577
- Protein C, activated, in coagulation, 578-580, 582
- Protein S
 - deficiency of, in antiphospholipid syndrome, 536
 - resistance to, in antiphospholipid syndrome, 536, 538
- Proteinase(s), in endothelial damage, 891
- Proteinase 3, anti-neutrophil cytoplasmic antibodies directed to. *See* Anti-neutrophil cytoplasmic antibodies, proteinase 3-directed.
- Prothrombin
 - activation fragments of, in antiphospholipid syndrome, 537
 - in coagulation, antiphospholipid antibodies and, 578, 581-582
- Proto-oncogenes, activation of, in rheumatoid arthritis, 356-357
- Psychologic impact, of osteoporosis, 256-259
- Puberty, bone development in, men versus women, 26
- Pulmonary embolism, in antiphospholipid syndrome, 516, 664-665
 - treatment of, 633-634
- Pulmonary hypertension, in antiphospholipid syndrome, 516-517, 530-531, 664-665
- Pulmonary-renal syndromes, anti-neutrophil cytoplasmic antibodies in, 807-808
- Pulse, loss of, in Takayasu's arteritis, 711-712
- Pupillary disturbances, in giant cell arteritis, 790
- Purpura
 - Henoch-Schönlein. *See* Henoch-Schönlein purpura.
 - in cryoglobulinemic vasculitis, 708-709
 - in drug-induced vasculitis, 854
- Raloxifene, for osteoporosis, 170-175, 178
 - estrogens with, 151
- Rash, maculopapular, in drug-induced vasculitis, 854
- Reactive oxygen species, in endothelial damage, 891
- Remodeling transient, bone, 102-103
- Renal vessels, thrombosis of, in antiphospholipid syndrome, 515
- Respiratory burst, anti-neutrophil cytoplasmic antibodies effects on, 819
- Retinopathy
 - in antiphospholipid syndrome, 510-511
 - in Behçet's disease, 771-772
 - in giant cell arteritis, 776-777, 782-784
 - in polyarteritis nodosa, 774
 - in systemic lupus erythematosus, 773
 - in Takayasu's arteritis, 774-775
 - in vasculitis, 765-766
- Rheumatoid arthritis, 317-354
 - anti-neutrophil cytoplasmic antibodies in, 801
 - cardiovascular disease in, 285-288, 294
 - comorbidity in, 283-303
 - early, treatment of, 405-414, 417-419
 - economic issues in, 283
 - endothelial dysfunction in, 897
 - epidemiology of, 269-281
 - incidence, 271-274
 - mortality, 274-275
 - prevalence, 274
 - gastrointestinal disease in, 293, 295-296
 - human leukocyte antigens in, 305-315
 - infections in. *See* Infections, in rheumatoid arthritis.
 - malignancy in, 288-290, 294, 431
 - mortality in, 274-275, 283-284
 - corticosteroid effects on, 395-396
 - ocular manifestations of, 772
 - osteoporosis in, 146, 164-165, 292-293, 295, 398
 - bone turnover markers in, 72
 - parathyroid hormone in, 229-230
 - pathogenesis of
 - B lymphocytes in, 335-353, 465
 - clinical aspects of, 373-387
 - immune function functional analysis, 376
 - synovitis characterization, 374-376
 - treatments developed from, 379-383
 - trials, 377-379
 - education and, 278

Rheumatoid arthritis (*Continued*)

- estrogens in, 277
 - genetic factors in, 275-276, 305-315
 - infections in, 276-277
 - smoking in, 277
 - synoviocytes in, 355-371
 - T lymphocytes in. *See* T lymphocytes, in rheumatoid arthritis pathogenesis.
 - tumor necrosis factor- α in, 319-320, 322, 378-383, 427-428
 - radiology in, corticosteroid effects on, 393-394
 - risk factors for, 275-278
 - treatment of
 - aggressive, 406-412
 - B lymphocyte-directed, 346
 - biological agents in. *See* Biologic agents, for rheumatoid arthritis; *specific agents*.
 - cardiovascular effects of, 287-288
 - corticosteroids in. *See* Corticosteroids, for rheumatoid arthritis.
 - disease-modifying antirheumatic drugs in, 415-426
 - gene therapy in, 467
 - human leukocyte antigen considerations in, 305-315
 - in early disease, 405-414, 417-419
 - pathogenesis information from, 377-379
 - tumor necrosis factor- α blockade in. *See* Tumor necrosis factor- α , blockade of.
 - window of opportunity for, 411-412
 - vasculitis in, 723-724, 742
 - Rheumatoid factor, in rheumatoid arthritis, 335-336, 340-341
 - Rheumatoid nodules, in Churg-Strauss syndrome, 702-703
 - Rheumatoid vasculitis, 723-724
 - Rib fractures, in osteoporosis, in men, 25
 - Rickets, bone disease in, 120-121
 - Risedronate, for osteoporosis, 168-169, 178, 205-206
 - glucocorticoid-induced, 245
- Saddle nose deformity, in Wegener's granulomatosis, 880
- Sagittal venous sinus thrombosis, in antiphospholipid syndrome, 508
- Sarcoidosis, vasculitis related to, 743
- Scleritis, in vasculitis, 761-763
- in rheumatoid arthritis, 773
 - in Wegener's granulomatosis, 768
- Sclerokeratitis, in vasculitis, 763-764
- Scott syndrome, 577
- Seizures, in antiphospholipid syndrome, 510
- Selective estrogen receptor modulators, for osteoporosis, 169-175, 178
- estrogens with, 151-152
- Serine proteinase 3, anti-neutrophil cytoplasmic antibodies directed to. *See* Anti-neutrophil cytoplasmic antibodies, proteinase 3-directed.
- Sex hormones. *See also specific hormones*.
- in osteoporosis, fracture risk and, 27-31
- Shwartzman reaction, in vasculitis, 834
- Sialoprotein, bone, as marker for bone resorption, 53-54
- Signal transduction, abnormalities of, in rheumatoid arthritis, 360-363
- Single energy densitometry, 82
- Sjögren's syndrome
- ocular manifestations of, 773
 - osteoporosis in, parathyroid hormone in, 229-230
- Skin disorders
- in antiphospholipid syndrome, 511-512
 - in drug-induced vasculitis, 854
 - in Henoch-Schönlein purpura, 689-693
 - in Takayasu's arteritis, 713
 - leukocytoclastic angitis, 741
- Smoking
- Buerger's disease in, 722
 - osteoporosis in, 31
 - rheumatoid arthritis in, 277
- Social impact, of osteoporosis, 259-260
- Sodium, intake of, calcium balance and, 106-107
- Somatic mutations, in rheumatoid arthritis, 357-360
- Spinal cord disorders, in antiphospholipid syndrome, 665
- Spine
- densitometry of, 95-96
 - in change monitoring, 95
 - morphometric measurements in, 97
 - quantitative computed tomography in, 85, 88
 - fractures of. *See* Vertebral fractures.
- Splinter hemorrhages, in Buerger's disease, 722
- Staphylococcal acid phosphatase, vasculitis related to, 842-843
- Staphylococcus aureus*, antigens to, vasculitis related to, 842-843, 896
- Strength, glucocorticoid effects on, 240-241
- Streptococcus pneumoniae* infections, antiphospholipid antibody induction in, 558
- Stroke
- in antiphospholipid syndrome, 508-509
 - in pregnancy, 646
 - prevention of, 539-540
 - treatment of, 634
 - versus central nervous system vasculitis, 716

- Stromelysin, in rheumatoid arthritis pathogenesis, 363
- Subglottic stenosis, in Wegener's granulomatosis, 700, 880
- Sulfasalazine, for rheumatoid arthritis early, 406-408, 410
in combinations, 417-418, 420-421
- Sural nerve, biopsy of
in Churg-Strauss syndrome, 705
in polyarteritis nodosa, 680
- Swimmers, bone status of, 137
- Synoviocytes, in rheumatoid arthritis, 355-371
matrix-modifying enzymes in, 322-323, 363-366
partial transformation of, 355-360
signal transduction in, 360-363
- Synovitis, in rheumatoid arthritis, pathogenesis of. *See* Rheumatoid arthritis, pathogenesis of.
- Synovium
biopsy of, in rheumatoid arthritis, 374-376
lymphocytic infiltration of, in rheumatoid arthritis, 343-345
- Syphilis, antiphospholipid antibodies in, 551-552
- Systemic lupus erythematosus
anti-neutrophil cytoplasmic antibodies in, 801
antiphospholipid antibodies in
atherosclerosis development and, 603-604
prognosis in, 662
tests for, 529
endothelial dysfunction in, 897
etanercept-induced, 435
immune complexes in, 834
infliximab-induced, 430-431
kidney transplantation in, 616-617
ocular manifestations of, 772-773
vasculitis in, epidemiology of, 742
- Systemic sclerosis, vasculitis in, epidemiology of, 742-743
- T lymphocytes
in endothelial damage, in vasculitis, 895-896
in rheumatoid arthritis pathogenesis, 317-334, 377-379, 381-383
apoptosis of, 465-466
as treatment targets, 446-454
costimulatory molecules in, 320-322
cytokines in, 319-320
effector mechanisms and, 326-328
function regulation and, 317-323
human leukocyte antigen DR4 in, 305-315
- lymphoid organogenesis and, 323-326
matricellular proteins in, 322-323
migration of, 318-319
receptor for, in rheumatoid arthritis vaccines, 450-451
- T-score, in densitometry, 92-94
- Tacrolimus
for Wegener's granulomatosis, 876
neurotoxicity of, 720
- Takayasu's arteritis
angiography in, 711, 713
back pain in, 710
bruit in, 710-711
C-reactive protein in, 711
cardiomyopathy in, 713
carotid bypass graft for, 714
epidemiology of, 732-734
erythrocyte sedimentation rate in, 711
genetic factors in, 732-733
ocular manifestations of, 774-775
pregnancy in, 713
pulse loss in, 711-712
skin lesions in, 713
treatment of, corticosteroids in, 714
- Tamoxifen, for osteoporosis, 175
- Tartrate-resistant acid phosphatase, as marker for bone resorption, 53-55
- TdT protein, abnormalities of, in rheumatoid arthritis, 345-346
- Telomerase, in rheumatoid arthritis, 357
- Temporal arteritis. *See* Giant cell (temporal) arteritis.
- Temporal artery, biopsy of, 683-687
- Testosterone, for osteoporosis
estrogens with, 150-151
fracture risk and, 28-30
glucocorticoid-induced, 244
in men, 38
- Tetracyclines, for rheumatoid arthritis, 466-467
- Throat, Wegener's granulomatosis manifestations in, 879-880
- Thrombin, in coagulation, antiphospholipid antibodies and, 578
- Thrombocytopenia, in antiphospholipid syndrome, 517
prognosis and, 664
treatment of, 639
- Thrombolytic therapy, for antiphospholipid syndrome, 634
- Thrombomodulin, in coagulation, antiphospholipid antibodies and, 579-580, 582
- Thrombophlebitis
in Behçet's disease, 719
in Buerger's disease, 721
- Thrombosis
in antiphospholipid syndrome, 501
acute, treatment of, 633-634
cardiac, 512-514, 554

Thrombosis (*Continued*)

- catastrophic, 634-635, 666
 - central nervous system, 507-511, 539-540, 665
 - coagulation cascade and, 573-586
 - cutaneous, 511-512
 - endothelial interactions in, 587-602
 - hematologic, 517-518
 - kidney, 514-516, 665
 - predictive tests for. *See* Antiphospholipid antibodies, tests for.
 - pulmonary, 516-517, 664-665
 - scope of, 633
 - transplantation and. *See* Transplantation.
 - treatment of, 633-642
 - acute, 633-634
 - catastrophic, 634-635
 - chronic, 635-640
 - in vasculitis, pathophysiology of, 894
- Thrombospondin, receptors for, in rheumatoid arthritis pathogenesis, 323
- Tibial fractures, in osteoporosis, epidemiology of, 6, 25
- Tissue factor, in coagulation, antiphospholipid antibodies and, 577-578
- Toxemia, of pregnancy, in antiphospholipid syndrome, 646
- Trachea, dilatation of, in Wegener's granulomatosis, 881
- Tracheostomy, in Wegener's granulomatosis, 881
- Transcription factors, in rheumatoid arthritis pathogenesis, 360-363
- Transplantation
- antiphospholipid antibodies and, 611-631
 - apoptosis in, 626-627
 - bone marrow, 623-626
 - fluorescence-activated cell sorter cross-matching in, 622-623
 - heart, 620-621
 - historical perspective of, 611-613
 - kidney, 516, 613-619
 - liver, 619-620
 - vascular grafts, 621-622
 - with left ventricular assist systems, 620-621
 - kidney, in Wegener's granulomatosis, 699-700
- Transverse myelopathy, in antiphospholipid syndrome, 665
- Trimethoprim-sulfamethoxazole for Wegener's granulomatosis, 873-874
- prophylactic, for Wegener's granulomatosis, 697
- Tuberculosis, in rheumatoid arthritis
- corticosteroids and, 397
 - tumor necrosis factor- α blocker-related, 438

Tumor necrosis factor- α

- chemical structure of, 427-428
 - in rheumatoid arthritis pathogenesis, 319-320, 327, 378-383, 427-428
 - inhibitors of
 - for rheumatoid arthritis, 380-381, 410, 427-443
 - biology of, 427-428
 - combination, 437-438
 - current agents for, 428-435. *See also* Etanercept; Infliximab.
 - future agents for, 435-438
 - infection surveillance in, 438
 - methotrexate with, 422
 - monoclonal antibodies in, 435-436
 - pathogenesis and, 428
 - small molecule type, 438
 - soluble receptors in, 436-437
 - unresolved issues in, 439-440
 - for Wegener's granulomatosis, 877
 - soluble form of, 427
- Tumor suppressor genes, mutations of, in rheumatoid arthritis, 357-360

Ulcer(s)

- corneal, in giant cell arteritis, 792
 - in Buerger's disease, 721-722
 - lower extremity, in polyarteritis nodosa, 681
 - skin, in antiphospholipid syndrome, 511-512
- Ultrasonography, quantitative, in bone density measurement, 88-90
- Urine, calcium excretion in, osteoporosis in, 106
- Urticarial vasculitis, 723
- Uveitis, in vasculitis, 764-765, 770-772

Vaccines

- T-cell receptor, in rheumatoid arthritis, 450-451
 - vasculitis due to, 850, 852
- Valvular heart disease, in antiphospholipid syndrome, 512-513
- Vascular bypass grafts, antiphospholipid antibodies and, 621-622
- Vasculitis. *See also* Arteritis; *specific diseases.*
- anti-neutrophil cytoplasmic antibodies in
 - clinical use of, 799-813
 - leukocyte-endothelial interactions in, 887-903
 - pathogenic significance of, 815-832, 833-848
 - central nervous system, 715-720
 - cryoglobulinemic, 708-710

- epidemiology of, 741
- immune complexes in, 834
- drug-induced, 849-862
 - anti-neutrophil cytoplasmic autoantibody-positive, 853-854
 - causal agents in, 849-853
 - clinical features of, 854
 - diagnosis of, 854-856
 - epidemiology of, 735
 - regulatory issues in, 850
 - research on, 857
 - treatment of, 856-857
 - vaccines and, 850, 852
- epidemiology of, 729-749
 - primary, 730-741
 - secondary, 742-743
- etiology of, 897-898
- historical background of, 677-678
- hypersensitivity. *See also* Vasculitis, drug-induced.
 - epidemiology of, 741
 - in Behçet's disease, 719-721, 743
 - in Buerger's disease, 721-723
 - in Churg-Strauss syndrome, 702-705
 - in dermatomyositis, 743
 - in Henoch-Schönlein purpura. *See* Henoch-Schönlein purpura.
 - in microscopic polyangiitis. *See* Microscopic polyangiitis.
 - in polymyositis, 743
 - in rheumatoid arthritis, 285, 742
 - in systemic lupus erythematosus, epidemiology of, 742
 - in Wegener's granulomatosis. *See* Wegener's granulomatosis.
- leukocytoclastic, immune complexes in, 834
- myths about. *See* Vasculitis, pearls and myths about.
- neuropathy in, 751-760
- nonsystemic, 756
- ocular manifestations of. *See* Ocular manifestations, of vasculitis; Giant cell (temporal) arteritis, visual manifestations of.
- pathogenesis of, anti-neutrophil cytoplasmic antibodies in. *See* Anti-neutrophil cytoplasmic antibodies, pathogenicity of.
- pearls and myths about, 677-728
 - Behçet's disease, 719-721
 - Buerger's disease, 721-723
 - central nervous system, 715-719
 - Churg-Strauss syndrome, 702-705
 - Cogan's syndrome, 714-715
 - cryoglobulinemic, 708-710
 - giant cell arteritis, 681, 683-688
 - Henoch-Schönlein purpura, 689-694
 - idiopathic rapidly progressive glomerulonephritis, 707-708
 - microscopic polyangiitis, 705-707
 - polyarteritis nodosa, 678-682
 - polymyalgia rheumatica, 688-689
 - rheumatoid, 723-724
 - Takayasu's arteritis, 710-714
 - urticarial, 723
 - Wegener's granulomatosis, 684-702
- renal-limited, 707-708
- retinal. *See* Retinopathy, in vasculitis.
- rheumatoid, 723-724
- urticarial, 723
- Wegener's granulomatosis. *See* Wegener's granulomatosis.
- Vasoactivity, of antiphospholipid antibodies, 596
- Venous thrombosis, in antiphospholipid syndrome, treatment of, 633-634
- Vertebral fractures, in osteoporosis
 - bisphosphonate effects on, 168-169
 - calcitonin effects on, 190-191
 - detection of, 166
 - epidemiology of, 5-6, 24-25
 - in men, 24-25, 32
 - morbidity in, 14
 - mortality in, 13
 - prediction of, densitometry in, 94
 - risk of, in estrogen deficiency, 144-145
 - treatment effects on, 177-180
 - with other fractures, 6-7
- Viral infections, antiphospholipid antibody induction in, 555-559
- Visceral abdominal angiography, in polyarteritis nodosa, 680-681
- Vision, loss of
 - in antiphospholipid syndrome, 510-511
 - in giant cell arteritis, 781
- Visual field defects, in giant cell arteritis, 787-789
- Visual hallucinations, in giant cell arteritis, 789
- Vitamin D, osteoporosis and, 117-125
 - deficiency, 120-121
 - dietary guidelines for, 120
 - food sources of, 120
 - forms of, 117-118
 - mechanism of action of, 117-119
 - metabolism of, 117-119
 - supplementation with, 122-125, 166-167
 - in calcitonin therapy, 193
 - in glucocorticoid therapy, 242-243, 879
 - in men, 37
 - toxicity, 122
- Warfarin, for antiphospholipid syndrome
 - acute, 633-634
 - chronic, 635-640
 - in pregnancy, 652
- Wassermann reagent, 551-552

Wegener's granulomatosis

- anti-endothelial cell antibody antigens in, 842

- anti-neutrophil cytoplasmic antibodies in, 836, 839-840, 842-843, 888-889
- monocytes and macrophages and, 822-823

- serologic testing and, 800, 804, 808

- cellular immunity in, 896

- chest radiography in, 695

- epidemiology of, 734-737

- hematuria in, 694-695

- immune complexes in, 838-840

- limited, treatment of, 864

- mortality in, 864

- necrotizing scleritis in, 762

- ocular manifestations of, 767-769

- refractory, versus opportunistic infection, 700-702

- severe, treatment of, 864

- Staphylococcus aureus* antigens in, 842-843, 896

- treatment of, 694-702, 863-886

- azathioprine in, 872

- biologic agents in, 877

- corticosteroids in, 698-699, 864-865, 869-871

- cyclophosphamide in, 695-697, 865-868, 878-879

- for remission induction, 864-871

- for remission maintenance, 871-874

- goals of, 863

- immune globulin in, 875-876

- in kidney failure, 882

- in nasal problems, 879-880

- in orbital inflammation, 881-882

- in otolaryngologic complications, 879-880

- in subglottic stenosis, 880-881

- kidney transplantation in, 699-700

- leflunomide in, 875

- limited, 864

- methotrexate in, 869-873

- mycophenolate mofetil in, 875

- neutropenia in, 697

- plasmapheresis in, 876

- prophylactic therapies in, 877-879

- severe, 864

- subglottic stenosis in, 700

- surgical, 698, 700

- trimethoprim-sulfamethoxazole in, 873-874

- versus Churg-Strauss syndrome, 702-703

- Weight, osteoporosis risk and, 31

- World Health Organization, osteoporosis criteria for, 20

- Wrist fractures, in osteoporosis, 6, 14

- Z-score, in densitometry, 92-93

